期刊
EXPERT OPINION ON EMERGING DRUGS
卷 22, 期 1, 页码 63-75出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/14728214.2017.1294159
关键词
Neuroblastoma; drug development; emerging drugs; targeted therapies; chemotherapy; high-dose chemotherapy; radiotherapy; immunotherapy; ALK inhibitors; PI3K/AKT/mTOR inhibitors
Introduction: Neuroblastoma is the most common solid extracranial tumor of childhood. Outcome for children with high-risk neuroblastoma remains suboptimal. More than half of children diagnosed with high-risk neuroblastoma either do not respond to conventional therapies or relapse after treatment with dismal prognosis. Areas covered: This paper presents a short review of the state of the art in the current treatment of high-risk neuroblastoma. An updated review of new targeted therapies in this group of patients is also presented. Expert opinion: In order to improve prognosis for high-risk patients there is an urgent need to better understand spatial and temporal heterogeneity and obtain new predictive preclinical models in neuroblastoma. Combination strategies with conventional chemotherapy and/or other targeted therapies may overcome current ALK inhibitors resistance. Improvement of international and transatlantic cooperation to speed clinical trials accrual is needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据